Novartis buys gene therapy company Vedere Bio for up to $280m

This article was originally published here

Under the deal, Vedere shareholders have secured $150m upfront payment and also eligible to secure up to $130m in milestone payments. Vedere Bio has an advanced platform for

The post Novartis buys gene therapy company Vedere Bio for up to $280m appeared first on Pharmaceutical Business review.